Halozyme Therapeutics (HALO) Non-Current Assets (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Non-Current Assets data on file, last reported at $1.7 billion in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $1.7 billion, up 78.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.2 billion (up 33.67% YoY), and the FY2025 annual result was $1.7 billion, up 73.81% from the prior year.
• Non-Current Assets declined to $1.7 billion in Q1 2026 per HALO's latest filing, from $1.7 billion in the prior quarter.
• Over five years, Non-Current Assets peaked at $1.7 billion in Q4 2025 and troughed at $173.6 million in Q1 2022.
• A 5-year average of $1.1 billion and a median of $991.1 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2023: Non-Current Assets surged 4646.49% in 2022, then slipped 16.32% in 2023.
• A 5-year view of Non-Current Assets shows it stood at $1.1 billion in 2022, then dropped by 10.49% to $986.8 million in 2023, then fell by 0.88% to $978.1 million in 2024, then soared by 73.81% to $1.7 billion in 2025, then decreased by 1.79% to $1.7 billion in 2026.
• Business Quant data shows HALO's Non-Current Assets at $1.7 billion in Q1 2026, $1.7 billion in Q4 2025, and $892.5 million in Q3 2025.